Thursday, December 19th, 2024

XPeng (9868 HK): Sustained Losses Amid Growth Challenges

XPeng (9868 HK): Sustained Losses Amid Growth Challenges

Recommendation: SELL

  • Target Price: HK$18.00
  • Date of Recommendation: September 9, 2024
  • Broker Company: UOB Kay Hian

Investment Thesis:

XPeng faces ongoing financial challenges, with sustained losses and cash outflows continuing to plague the company. Despite recent sales growth driven by its sub-brand Mona, XPeng’s profitability remains a concern, leading to the sell recommendation.

Key reasons for the negative outlook include:

  • Sales Growth Offset by Losses: XPeng saw a 13% yoy increase in insurance registrations in the 35th week of 2024, reaching 3,500 units. However, despite the positive sales trend, XPeng is expected to report a net loss of RMB7.80 billion for 2024, with continued losses projected through 2026.
  • Mona’s Contribution: The introduction of the Mona sub-brand has boosted sales, but it is insufficient to reverse the company’s overall financial trajectory. XPeng’s net losses for 2024-2026 are forecasted at RMB7.80 billion, RMB6.13 billion, and RMB5.22 billion, respectively.

Financial Performance:

  • Wholesale Shipments: XPeng’s wholesale shipments grew by 3% yoy to 14,036 units in August 2024, bringing the YTD total to 77,209 units.

Valuation and Catalysts:

The target price of HK$18.00 reflects XPeng’s ongoing financial difficulties and the uncertain outlook for profitability. Despite recent sales growth, the company’s cash burn and losses justify the sell recommendation.

Thank you

ST Engineering: Set to Soar with New Defense Contracts and Strong Growth Potential

Date of Report October 3, 2024 Broker Name CGS International Company Overview ST Engineering Ltd is a global technology, defense, and engineering group that leverages innovation to solve complex problems across various sectors, including...

Simcere Pharmaceutical (2096.HK) Shows Bullish Trend: Technical Analysis Points to Upside Potential

Trendspotter: In-Depth Analysis of Hong Kong Retail Stocks Broker Name: CGS International Securities Date of Report: December 4, 2024 Simcere Pharmaceutical Group Ltd (2096): A Bullish Outlook Simcere Pharmaceutical Group Ltd has shown a...

Tencent Stock: Strong Q3 Earnings Beat and Growth Drivers Ahead for Chinese Tech Giant

Equity Research Analysis: Tencent Holdings and Its Market Position Broker: OCBC Investment Research Date: 14 November 2024 Introduction As we navigate through the intricate world of financial markets, understanding the dynamics of leading companies...